The recently unveiled conjugate DS3610a is to start phase 1.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Summit and Nuvalent have scored prized plenary spots.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Inclacumab fails, and osivelotor is on hold.
Shortly after ponsegromab, visugromab is to start phase 2/3.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
